Welcome to our dedicated page for Trinity Biotech Plc news (Ticker: TRIB), a resource for investors and traders seeking the latest updates and insights on Trinity Biotech Plc stock.
Trinity Biotech plc (NASDAQ: TRIB) is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The TRIB news feed on Stock Titan aggregates company press releases and related coverage so readers can follow developments across its infectious disease, diabetes, oncology and maternal health portfolios.
News items for Trinity Biotech commonly highlight regulatory milestones and product launches. Recent announcements include large orders for its TrinScreen HIV rapid screening test, WHO and in-country regulatory approvals enabling offshored and outsourced manufacturing of TrinScreen HIV and Uni-Gold HIV, and expanded rollout of a high-capacity HbA1c column system for the FDA-cleared Premier Hb9210 analyzer. These updates provide insight into how the company is executing its transformation plan and adjusting its manufacturing footprint.
Investors and observers can also use the TRIB news page to track progress in newer areas such as continuous glucose monitoring, where the company has reported breakthrough clinical trial results for a redesigned CGM sensor and references its CGM+ solution, as well as oncology and maternal health initiatives, including development of the EpiCapture prostate cancer test and the PreClara Ratio preeclampsia biomarker service. Capital structure and governance developments, such as credit agreement amendments with Perceptive Advisors, Nasdaq listing compliance updates, and annual general meeting outcomes, are also disclosed through news and associated SEC filings.
By reviewing the Trinity Biotech news stream, users can see how product approvals, manufacturing changes, financing arrangements and clinical data releases intersect with the company’s stated strategy in diagnostics and diabetes management. This page can be revisited to follow new regulatory clearances, commercial orders, pipeline updates and corporate actions as they are reported by the company.
Trinity Biotech (Nasdaq: TRIB) entered a collaboration with the University at Buffalo to co-develop and commercialize a proprietary suite of biomarkers for earlier, more accurate detection of Sjögren’s Syndrome.
The agreement leverages biomarkers licensed to Trinity subsidiary IMMCO, UB CAT funding support, and Trinity’s NYSDOH-approved reference laboratory as the U.S. launch platform.
Trinity Biotech (Nasdaq: TRIB) announced it has begun commercial rollout in Brazil of its upgraded Premier Hb9210™ HbA1c column system following local regulatory approval on March 12, 2026.
The Premier Hb9210™ is the only HbA1c system awarded IFCC Gold for 2026. Trinity also appointed Bruna Gigliotti to lead its Brazilian commercial organisation to support market adoption.
Trinity Biotech (Nasdaq: TRIB) will attend ATTD 2026 in Barcelona to accelerate partnerships and commercialization planning for its next‑generation CGM platform, CGM+. Recent clinical performance supported the decision to advance the program into a pivotal clinical trial in 2026, with results indicating the system can meet modern CGM accuracy standards.
Executives will engage prospective collaborators across clinical research, technology integration, and commercial distribution ahead of the pivotal trial.
Trinity Biotech (Nasdaq: TRIB) announced technical breakthroughs advancing its next-generation, finger‑stick calibration‑free CGM system, CGM+, reporting >650 days of clinical testing data and a material reduction in MARD across multi-day wear. The company expects to initiate a pivotal clinical trial in 2026 and highlights a modular, AI-native, multimodal device design aimed at lower cost and improved sustainability versus current CGMs.
The release cites needle-free insertion advances, multimodal sensing for personalized metabolic insights, and market opportunity context (global CGM ~$15.3B projected 2026).
Trinity Biotech (Nasdaq: TRIB) provided a Q4 2025 trading update and business progress report. The company expects Q4 2025 revenue of $11.5M–$12.5M, down from $15.9M in Q4 2024, driven by HIV testing market disruptions and manufacturing transitions.
Key developments include February 2026 local approval to outsource Uni-Gold manufacturing, continued commercial traction for Uni-Gold and TrinScreen, IFCC Gold classification for its HbA1c solution, and ongoing pipeline work on CGM+, EpiCapture, and PrePsia.
Trinity Biotech (Nasdaq: TRIB) entered a $25 million Standby Equity Purchase Agreement (SEPA) with a Yorkville affiliate dated Feb 25, 2026 to provide up to 36 months of discretionary funding. The facility permits sales of ADSs at discounts of 97% (3-day VWAP) or 95% (1-day VWAP), subject to resale registration, trading-volume caps and a 4.99% Yorkville ownership limit. Trinity reported $48.6 million revenue for the 12 months ended Sept 30, 2025 and cited strengthened HIV testing sales and later-stage progress on its CGM+ needle-free glucose sensor following August 2025 trial results.
Trinity Biotech (Nasdaq: TRIB) received a Nasdaq notice on Feb 19, 2026 saying it no longer meets the $15,000,000 minimum market value of publicly held shares (MVPHS) requirement under Nasdaq Rule 5450(b). The notice imposes a 180-calendar-day cure period ending Aug 18, 2026, during which the company must exceed $15,000,000 MVPHS for at least 10 consecutive business days to regain compliance. ADSs continue trading on the Nasdaq Global Select Market while the company evaluates options, including restoring market value, seeking transfer to The Nasdaq Capital Market if eligible, or appealing any delisting determination.
Trinity Biotech (Nasdaq: TRIB) received a Nasdaq notice on Feb 11, 2026 that it is not in compliance with Nasdaq Listing Rule 5450(a)(1) because its ADS closing bid price fell below $1.00 for the prior 30 consecutive business days.
The ADSs continue to trade on the Nasdaq Global Select Market. The company has 180 calendar days, until Aug 10, 2026, to regain compliance by achieving a $1.00 closing bid for at least 10 consecutive business days. If not cured, eligibility for a second compliance period requires meeting the MVPHS $15,000,000 and other listing standards for The Nasdaq Capital Market. Management is evaluating options to cure the deficiency and maintain listing.
Trinity Biotech (Nasdaq: TRIB) received final local regulatory approval to begin upstream manufacturing of its WHO‑prequalified Uni‑Gold™ HIV rapid test under an offshored and outsourced production model. This clearance completes the regulatory milestones needed to implement the new manufacturing approach.
The company says the transition to offshore upstream processes is expected to expand gross margins, improve working capital efficiency, and enhance scalability, supporting its Comprehensive Transformation Plan and long‑term financial profile. The approval follows WHO authorisation in November 2025.
Trinity Biotech (Nasdaq: TRIB) announced its Premier Hb9210™ HbA1c Analyser with the next-generation Buffer A Plus column system received the IFCC Gold Classification for 2026, making it the only HbA1c system worldwide to earn Gold status for 2026.
The certification reflects top-tier analytic precision and bias among >200 systems evaluated. Trinity highlights its ~$100 million cumulative investment in diabetes technologies and notes the global laboratory HbA1c market exceeds $2 billion, projected to surpass $3.5 billion by 2030. Senior commercial executives will attend the World Health Expo Feb 10–12, 2026 to discuss these advances.